QuidelOrtho Fires its President and CEO

QuidelOrtho Corporation’s has restructured its executive team. The company’s Board of Directors has fired President/CEO Douglas Bryant after a “comprehensive evaluation.” The board did not provide a reason for Bryant’s termination, but said he has also resigned from the governing body.
 
To ensure business continuity, the board formed the Office of the Chief Executive Officer; that office is now led by Executive Vice President/Chief Commercial Officer Michael Iskra, Executive Vice President/Chief Operating Officer (COO) Robert Bujarski, and Chief Financial Officer Joseph Busky.
 
The board also appointed Iskra as interim CEO and Bujarski as interim president. Both continue to fulfill their current responsibilities while assuming the additional duties of their new roles. Kenneth F. Buechler, Ph.D., remains board chairman and will provide guidance to the Office of the CEO, along with other board members.

Iskra has more than a decade of global executive leadership experience and over 30 years of experience in the diagnostics and healthcare products and services industries. He has significant knowledge and expertise across strategy, sales, marketing, operations, and general management. Prior to his current role, lskra was executive vice president of Commercial Excellence and Strategy at Ortho Clinical Diagnostics Holdings plc from 2020 to 2022.
 
Bujarski has two decades of enterprise experience at the company, spanning the full spectrum of operational, commercial, and legal functions within the diagnostics sector. Bujarski also brings to his new role significant knowledge and expertise across strategy, business development and R&D. Prior to his current job, Bujarski was COO of Quidel Corporation from September 2020 to May 2022, where he orchestrated expansions of Quidel’s operational scope and scale.
 
“Now is the time for a change in leadership that can accelerate our initiatives to improve efficiencies, drive growth and increase shareholder value,” Buechler said. “All of us would like to thank Doug for his years of dedication and wish him well in his future endeavors.”
 
The board is now searching for Bryant’s permanent replacement and is considering both internal and external candidates. 

QuidelOrtho Corporation develops and manufactures in-vitro diagnostic solutions that transform data into understanding and action. Offering expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, the company produces fast, accurate and reliable diagnostics when and where they are needed—the home, hospital, lab, or clinic. QuidelOrtho partners with customers across the healthcare continuum and worldwide to advance diagnostics.